Retinal toxicity screening underused for hydroxychloroquine therapy│ EULAR

Access to the full content of this site is available only to registered healthcare professionals. Register to read more


  • There were significant deficiencies in guideline-based screening in Irish patients treated with hydroxychloroquine (HCQ) for connective tissue disease, with a high level of toxicity shown in patients who did undergo screening.   

Why this matters 

  • HCQ-related visual toxicity is usually permanent with possible progression up to years after drug cessation and with no current treatment available. 
  • Early detection is essential for preserving central vision and foveal architecture. 

Study design

  • Investigators examined the medical records of 161 patients with connective tissue disease treated at a regional rheumatology center in order to determine compliance with the American Academy of Ophthalmology Recommendation on Screening for Chloroqui...